SCHEMBL9661

SCHEMBL9661

COc1ccc(CNc2nc3cc(F)c(Br)cc3cc2C=CC(=O)NCC2CCCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
RECQL P46063 1/20 0.44
USP30 Q70CQ3 1/20 0.43
POLB P06746 1/20 0.42
KMT2A Q03164 2/20 0.41
HDAC1 Q13547 3/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC3 O15379 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC4 P56524 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
HDAC2 Q92769 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9660 1.00 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ERECQLUSP30
SCHEMBL14322549 0.89 ALDH1A1 (0.46) ALDH1A1MAPTKDM4ERECQLUSP30
SCHEMBL14322551 0.89 ALDH1A1 (0.46) ALDH1A1MAPTKDM4ERECQLUSP30
SCHEMBL8781 0.83 MAPT (0.41) ALDH1A1MAPTKDM4ERECQLPOLB
SCHEMBL13906 0.83 MAPT (0.41) ALDH1A1MAPTKDM4ERECQLKMT2A
SCHEMBL8782 0.83 MAPT (0.41) ALDH1A1MAPTKDM4ERECQLPOLB
SCHEMBL13348 0.83 KMT2A (0.47) ALDH1A1POLBKMT2ANPC1RAB9A
SCHEMBL9137 0.81 POLB (0.42) ALDH1A1MAPTKDM4ERECQLPOLB
SCHEMBL9909 0.78 MAP2K4 (0.41) MAPTPOLBKMT2ANPC1RAB9A
SCHEMBL14321784 0.77 VNN1 (0.39) ALDH1A1MAPTKDM4EKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP ALDH1A1 1846/4885MAPT 809/4885KDM4E 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.